Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies

Bibliography

• Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-years population-based study. Arch Intern Med 1998;158:585-93
   PubMed Web of Science ®Google Scholar
• White RH. The epidemiology of venous thromboembolism. Circulation 2003;107(23 Suppl 1):I4-8
   PubMed Web of Science ®Google Scholar
• Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 1991;151:933-8
   PubMed Web of Science ®Google Scholar
• Prandoni P, Noventa F, Ghirarduzzi A, et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007;92:199-205
   PubMed Web of Science ®Google Scholar
• Stain M, Schönauer V, Minar E, et al. The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease. J Thromb Haemost 2005;3:2671-6
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350:2257-64
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):e419S-94S
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e24S-43S
   PubMed Web of Science ®Google Scholar
• Junqueira DR, Perini E, Penholati RR, et al. Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients. Cochrane Database Syst Rev 2012;9:CD007557
   PubMedGoogle Scholar
• Jeske W, Wolf H, Ahsan A, et al. Pharmacologic profile of certoparin. Expert Opin Investig Drugs 1999;8:315-27
   PubMedGoogle Scholar
• Fareed J, Walenga JM, Hoppensteadt D, et al. Chemical and biological heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin Thromb Hemost 1989;15:440-63
   PubMed Web of Science ®Google Scholar
• Grobecker H, Welzel D, Dittrich W, et al. Pharmakokinetik und Bioverfubarkeit von nieder-molekularenHeparin-Sandoz mit 1500 und 2500 aPTT Einheiten. Study Report 1994
   Google Scholar
• Welzel D. Clinical and pharmacological aspects of LMW heparins in the prophylaxis of thromboses. Haemostasis 1986;141
   Google Scholar
• Scheuch G, Brand P, Meyer T. Anticoagulative effects of the inhaled low molecular weight heparin certoparin in healthy subjects. J Physiol Pharmacol 2007;58(Suppl 5(Pt 2):603-14
   PubMedGoogle Scholar
• Kirchmaier CM, Wolf H, Schäfer H, et al. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group. Int Angiol 1998;17:135-45
   PubMed Web of Science ®Google Scholar
• Harenberg J, Schmidt JA, Koppenhagen K, et al. Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. Thromb Haemost 2000;83(5):652-6
   PubMed Web of Science ®Google Scholar
• Harenberg J, Huisman MV, Tolle AR, et al. Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin. Semin Thromb Hemost 2001;27(5):513-18
   PubMed Web of Science ®Google Scholar
• Riess H, Koppenhagen K, Tolle A, et al. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thromb Haemost 2003;90(2):252-9
   PubMed Web of Science ®Google Scholar
• Harenberg J, Riess H, Büller HR, et al. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin. Haematologica 2003;88(10):1157-62
   PubMedGoogle Scholar
• Horbach T, Wolf H, Michaelis HC, et al. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb Haemost 1996;75(2):246-50
   PubMed Web of Science ®Google Scholar
• Adolf J, Fritsche HM, Haas S, et al. Comparison of 3,000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group. Int Angiol 1999;18(2):122-6
   PubMed Web of Science ®Google Scholar
• Bramlage P, Michaelis HC, Melzer N. Comparison of 3,000 and 5,000 IU aXa/day certoparin in the prevention of deep-vein thrombosis after total hip replacement. Thromb J 2012;10(1):10
   PubMedGoogle Scholar
• Kolb G, Bodamer I, Galster H, et al. Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. Thromb Haemost 2003;90(6):1100-5
   PubMed Web of Science ®Google Scholar
• Haas S, Wolf H, Kakkar AK, et al. Prevention of fatal pulmonary embolism and mortality in surgical patients: a randomized double-blind comparison of LMWH with unfractionated heparin. Thromb Haemost 2005;94(4):814-19
   PubMed Web of Science ®Google Scholar
• Schellong SM, Haas S, Greinacher A, et al. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. Expert Opin Pharmacother 2010;11(18):2953-61
   PubMed Web of Science ®Google Scholar
• Riess H, Haas S, Tebbe U, et al. A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. J Thromb Haemost 2010;8(6):1209-15
   PubMed Web of Science ®Google Scholar
• Haas S, Schellong SM, Tebbe U, et al. Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. BMC Cancer 2011;11:316
   PubMedGoogle Scholar
• Schellong SM, Gerlach HE, Tebbe U, et al. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thromb Res 2011;128(5):417-21
   PubMed Web of Science ®Google Scholar
• Bauersachs R, Schellong SM, Haas S, et al. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 2011;105(6):981-8
   PubMed Web of Science ®Google Scholar
• Diener HC, Ringelstein EB, von Kummer R, et al. Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. Stroke 2006;37(1):139-44
   PubMed Web of Science ®Google Scholar
• Haas SK, Freund M, Heigener D, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost 2012;18(2):159-65
   PubMed Web of Science ®Google Scholar
• Jochberger S, Mayr V, Luckner G, et al. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 2005;9(5):R541-8
   PubMed Web of Science ®Google Scholar
• Diener HC, Ringelstein EB, von Kummer R, et al. Treatment of acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the TOPAS trial. Therapy of Patients With Acute Stroke (TOPAS) Investigators. Stroke 2001;32(1):22-9
   PubMed Web of Science ®Google Scholar
• Sandercock PA, Gibson LM, Liu M. Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev 2009(2):CD000248
   Google Scholar
• Tebbe U, Oeckinghaus R, Appel KF, et al. AFFECT: a prospective, open-label, multicenter trial to evaluate the feasibility and safety of a short-term treatment with subcutaneous certoparin in patients with persistent non-valvular atrial fibrillation. Clin Res Cardiol 2008;97(6):389-96
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S-75S
   PubMed Web of Science ®Google Scholar
• Grassman ED, Leya F, Fareed J, et al. A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol 2001;13(11):723-8
   PubMedGoogle Scholar
• Harrington RA, Becker RC, Cannon CP, et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: american College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):670S-707S
   Web of Science ®Google Scholar
• Dorsch O, Krieter DH, Lemke HD, et al. A multi-center, prospective, open-label, 8-week study of certoparin for anticoagulation during maintenance hemodialysis - the membrane study. BMC Nephrol 2012;13:50
   PubMedGoogle Scholar
• Spannagl M, Melzer N, Bramlage P, et al. Prospective, non-interventional study on the real-world use of certoparin in daily practice–The promember STUDY. Clin Appl Thromb Hemost 2013;19(1):86-91
   PubMed Web of Science ®Google Scholar
• Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 2010;115(9):1797-803
   PubMed Web of Science ®Google Scholar